OPGN - OpGen, Inc.
1.55 -0.14 (-8.28%)
After hours: 7:59PM EDT
| Previous Close | 1.86 |
| Open | 1.86 |
| Bid | 1.55 x 1000 |
| Ask | 1.79 x 2900 |
| Day's Range | 1.68 - 1.85 |
| 52 Week Range | 1.62 - 10.25 |
| Volume | 294,454 |
| Avg. Volume | 92,104 |
| Market Cap | 10.497M |
| Beta (3Y Monthly) | 1.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.60 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.60 |
- GlobeNewswire•6 hours ago
OpGen Announces Proposed Public Offering of Common Stock
OpGen, Inc. (OPGN) today announced that it has commenced an underwritten public offering of its common stock. All of the shares are being offered by OpGen, Inc. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds of this offering for research and development, including funding the continued development and manufacturing of its Acuitas® AMR Gene Panel tests, including its Acuitas AMR Gene Panel u5.47 that was released for Research Use Only in February 2018 and its Acuitas Lighthouse® software, to support acquisitions of products and technologies, capital expenditures, working capital and other general corporate purposes.
- GlobeNewswire•2 days ago
OpGen Provides Business and Preliminary Financial Update
OpGen, Inc. (OPGN) today provided an update on its commercial activities and clinical trials for its Acuitas® AMR Gene Panel tests and the Acuitas Lighthouse® Software. Preliminary unaudited results for the third quarter of 2018 were also reported. OpGen continues to make commercial progress with the Acuitas AMR Gene Panel and the Acuitas Lighthouse Software Research Use Only (RUO) products.
- GlobeNewswire•22 days ago
OpGen to Present at Two Upcoming Investment Conferences in October
GAITHERSBURG, Md., Sept. 25, 2018 -- OpGen, Inc. (NASDAQ: OPGN) announced today that Evan Jones, Chairman and Chief Executive Officer, will present a corporate overview at two.
- GlobeNewswire•24 days ago
OpGen Partnering with New York State Department of Health and Merck’s ILÚM Health Solutions to Detect Antimicrobial-Resistant Infections
OpGen, Inc. (OPGN) announced today a groundbreaking collaboration with the New York State Department of Health (“DOH”) and ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of Merck’s Healthcare Services and Solutions, to develop a state-of-the-art research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide.
- GlobeNewswire•2 months ago
OpGen to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
GAITHERSBURG, Md., Aug. 29, 2018-- OpGen, Inc. announced today that Evan Jones, Chairman and Chief Executive Officer, will present a corporate overview at the 20 th Annual Rodman & Renshaw Global Investment ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of OPGN earnings conference call or presentation 2-Aug-18 8:30pm GMT
Q2 2018 OpGen Inc Earnings Call
- GlobeNewswire•2 months ago
OpGen Reports Second Quarter 2018 Financial Results And Provides Business Update
Revenue increases 12% to $0.8 million, net loss narrows 21% to $3.3 million. Conference call begins at 4:30 p.m. Eastern time today. GAITHERSBURG, Md., Aug. 02, 2018-- OpGen, Inc. today reported financial ...
- ACCESSWIRE•2 months ago
OpGen, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / OpGen, Inc. (NASDAQ: OPGN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern Time. To listen ...
- Zacks•3 months ago
Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS
Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS
- InvestorPlace•3 months ago
5 Top-Ranked Stocks to Benefit From Rising P/E Investing
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The idea is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not validate (is not equivalent to) its higher earnings and therefore has room to run justifies investors’ inclination toward low P/E stocks.Source: ©iStock.com/CharlieAJA
- Zacks•3 months ago
5 Top-Ranked Stocks to Benefit From Rising P/E Investing
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
- GlobeNewswire•3 months ago
OpGen Announces Date of Second Quarter 2018 Financial Results Conference Call
GAITHERSBERG, Md., July 25, 2018-- OpGen, Inc. today announced that the Company will report financial results for the three and six months ended June 30, 2018 after close of the U.S. financial markets ...
- ACCESSWIRE•3 months ago
Free Pre-Market Technical Recap on ResMed and Three Additional Healthcare Stocks
On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), OpGen Inc. (NASDAQ: OPGN), and Organovo Holdings Inc. (NASDAQ: ONVO). On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 373,287 shares.
- ACCESSWIRE•5 months ago
Free Stock Performance Review on Organovo Holdings and Three Additional Medical Research Stocks
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on ONVO sign up now at www.wallstequities.com/registration. Durham, North Carolina headquartered IQVIA Holdings Inc.'s stock finished Wednesday's session 1.31% higher at $100.48 with a total trading volume of 968,866 shares. Over the last month and the previous three months, the Company's shares have advanced 4.93% and 2.19%, respectively.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of OPGN earnings conference call or presentation 8-May-18 8:30pm GMT
Q1 2018 OpGen Inc Earnings Call
- ACCESSWIRE•6 months ago
With FDA Filing On The Horizon, NMTC Could Pull an EBIO-Like Move
Newly public NeuroOne (NMTC) could be one of these movers in 2018 as they plan to file their first FDA medical device submission in the upcoming months. This technology addresses a large market opportunity and could support multiples of upside.
